在晚期癌症患者中使用德克萨米他治疗严重疲劳:简要报告
Gemma Ingham1, Kat Urban2, Yinyin Phyo3
1Department of Palliative Care, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Palliative medicine reports
|April 1, 2024
概括
德克萨米他显示出在息护理患者中管理疲劳的潜力,观察到疲劳得分的改善. 虽然它没有被广泛用于此目的,但这项研究表明,它通常被很好地容忍,并具有可控的副作用.
科学领域:
- 抚慰性护理医学 抚慰性护理医学
- 瘤学 支持性护理 支持性护理
- 临床药理学 临床药理学
背景情况:
- 疲劳是息护理中普遍存在和使人虚弱的症状.
- 强调非药理干预措施,但据报道德克萨米他被非标签使用.
- 有限的现实世界的数据存在于德克萨米他的有效性和安全性对于疲劳在这个人群.
研究的目的:
- 研究德克萨米他在息护理中对疲劳管理的临床使用,有效性和不良事件概况.
- 加强关于德克萨米他在缓解疲劳症状中的作用的证据基础.
主要方法:
- 国际,多站点前性观察案例系列.
- 使用症状评估量表 (SAS) 和视觉模拟疲劳量表 (VAFS) 在基线 (T0) 和治疗后5-7天 (T1) 评估疲劳.
- 使用NCI-CTCAE对不良事件进行分级;统计分析采用Wilcoxon签名等级测试.
主要成果:
- 18名晚期癌症患者参与,主要是在恶化的息阶段 (56%).
- 常见的剂量是每天4毫克口服德克萨米他.
- 在T1观察到中位数SAS得分 (7至5.5,p=0.007) 的显著改善以及VAFS和NCI-CTCAE疲劳得分的改善趋势.
- 德克萨米他的耐受性一般很好,有一例3级妄想症.
结论:
- 由于招募人数有限,这表明德克萨米他不是缓和护理中疲劳的主要治疗方法.
- 结果表明,德克萨米他在改善疲劳分数方面具有潜在的益处.
- 需要进一步的研究来证实这种患者群的有效性和最佳使用.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
281
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
281
Fatigue
181
Fatigue occurs when materials rupture under repeated or fluctuating loads, even at stress levels far below their static breaking strength. It typically results in brittle failure, even for ductile materials. It is a critical consideration in designing machines and structural components subjected to repetitive or varying loads. The nature of these loadings can range from fluctuating loads like unbalanced pump impellers causing vibrations to repeatedly bending a thin steel rod wire back and forth...
181
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
200
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200
Muscle Recovery and Fatigue
2.1K
Muscle fatigue refers to the decline in a muscle's ability to maintain the force of contraction after prolonged activity. It primarily stems from changes within muscle fibers. Even before experiencing muscle fatigue, one may feel tired and have the urge to stop the activity. This response, known as central fatigue, occurs due to changes in the central nervous system, namely the brain and spinal cord. While there is no single mechanism that induces fatigue, it may serve as a protective...
2.1K
COPD: Management Using Bronchodilators and Corticosteroids
202
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
202


